Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (APTO)
NASDAQ:APTO
Aptose Biosciences (APTO) Stock Price & Analysis
1,203 Followers
APTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $5.10
Previous Close$0.66
Volume121.35K
Average Volume (3M)65.31K
Market Cap
$11.74M
Enterprise Value$3.33M
Total Cash (Recent Filing)$9.33M
Total Debt (Recent Filing)$919.00K
Price to Earnings (P/E)―
Beta0.06
Next Earnings
Aug 06, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.27
Shares Outstanding20,164,393
10 Day Avg. Volume90,217
30 Day Avg. Volume65,307
Standard Deviation0.26
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-5.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$6.50Price Target Upside884.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aptose Biosciences News
PremiumCompany Announcements
Aptose Biosciences Faces Nasdaq Delisting Challenge
PremiumCompany Announcements
Aptose Biosciences Shareholders Approve Key ProposalsPremiumCompany Announcements
Aptose Biosciences Issues Non-Filed Information Disclosure
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTuspetinib is shaping up to be a welcome addition to first-line advanced AML.
Safety And EfficacyCombination therapy with tuspetinib is safe and well tolerated.
Treatment OutcomesIncorporating tuspetinib into r/r AML treatment regimens could permit treatment of more patients, improvement in safety outcomes, enhancement of survival outcomes, and avoiding common first-line therapeutic failures.
Bears Say
EarningsThe price target is lowered to $6 from $15, reflecting expectations for a later FDA and EMA approval of tuspetinib in AML.
Financial PerformanceRecent share dilution to ~13M shares in early 2024 from ~7M shares in late 2023.
Treatment EfficacyThe median duration of remission for responding patients administered VEN/AZA is approximately 18 months, and a substantial number of patients finally relapse.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APTO FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was $0.59 and its highest was $5.10 in the past 12 months.
What is Aptose Biosciences’s market cap?
Currently, no data Available
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on May 14, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$1.097 by $0.367.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -$0.56.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 18,109,392 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -$0.73 in its last earnings report, beating expectations of -$1.097. Following the earnings report the stock price went down -4.065%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Among the largest hedge funds holding Aptose Biosciences’s share is Carlson Capital LP. It holds Aptose Biosciences’s shares valued at N/A.
---
Aptose Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (884.85% Upside)
$6.50 (884.85% Upside)
Hedge Fund Trend
Decreased
By 96.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.72%
12-Months-Change
Fundamentals
Return on Equity
-361.05%
Trailing 12-Months
Asset Growth
-67.47%
Trailing 12-Months
Company Description
Aptose Biosciences
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
---
APTO Earnings Call
Q1 2024
0:00 / 0:00
---
APTO Stock 12 Month Forecast
Average Price Target
$6.50
▲(884.85% Upside)
Technical Analysis
Best Analysts Covering APTO
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-17.54%
reiterated a buy rating 9 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -17.54% per trade.
---